RCP
VRTX icon

Rothschild Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Rothschild Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,888
Closed -$334K – 88
2016
Q2 		$334K Buy
+3,888
New +$336K 0.13% 47

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rothschild Capital Partners's VRTX Position: Q3 2016 in Review

Rothschild Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2016, closing a stake of 3,888 shares — an estimated $334K sold.

Rothschild Capital Partners first reported a position in VRTX in Q2 2016 and held it in 1 quarter. The position peaked at $334K in Q2 2016. 491 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

  • Rothschild Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Rothschild Capital Partners sold 3,888 Vertex Pharmaceuticals shares in Q3 2016, an estimated $334K.
  • Rothschild Capital Partners first reported a position in Vertex Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Rothschild Capital Partners's Vertex Pharmaceuticals position peaked at $334K in Q2 2016.
  • 491 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on Rothschild Capital Partners's 13F filing for Q3 2016, filed 1 Nov 2016.